Topics

Glioblastoma | Treatment | Targeted therapy | Lisavanbulin

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Lisavanbulin

Holdhoff M, Ye X, Strowd RE, Nabors B, Walbert T, Lieberman FS, Bagley SJ, Fiveash JB, Fisher JD, Desideri S, Surakus T, Engelhardt M, Kaindl T, Lane HA, Litherland K, Grossman SA, Kleinberg LR.
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Neurooncol Adv. 2024 Aug 28;6(1):vdae150. doi: 10.1093/noajnl/vdae150. PMID: 39371261. Interventional study. ˍ

Lopez JS, Haefliger S, Plummer R, Clement PM, Jeffry Evans TR, Läubli H, Roth P, Kristeleit R, Brazil L, Tabatabai G, Wick A, Wunderlich B, Beebe K, Eisner JR, Lane H, Engelhardt M, Kaindl T, Hau P, Hundsberger T, Steinbach J.
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Cell Rep Med. 2025 Jun 17;6(6):102165. doi: 10.1016/j.xcrm.2025.102165. PMID: 40532659. Interventional study. ˍ